Skip to main content
Smart Investors Daily
CA

NASDAQ · CASI

CASI Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.15

Up+$0.00 (+3.08%)

Updated Oct 10, 2026, 4:33 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.49M
P/E ratio
-0.3
Dividend yield
0.00%
52-week range
— – —
Volume
7.9K
Avg. volume
120.21K

Price performance · CASI

CASI price history

1M range · 0 trading sessions · Daily adjusted prices

CASI does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CASI news

The latest Smart Investors Daily articles mentioning CASI.

CASI research

Overview

Company profile and research snapshot.

Company profile

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
CASI recent ratings
DateFirmRatingTarget
Sep 3, 2025HC Wainwright & Co.Buy—
May 19, 2025HC Wainwright & Co.Buy—
Apr 9, 2025HC Wainwright & Co.Buy—
May 15, 2024HC Wainwright & Co.Buy—
Nov 15, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

ChartMill · Feb 25, 2026

Top movers in Wednesday's after hours session

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.